Glaxo inks $330M pact for Apeiron lung drug

GlaxoSmithKline is willing to wager up to $330 million on an early-stage lung disease drug in Apeiron Biologics' pipeline. The Austrian biotech struck the deal on APN01, an enzyme biotherapeutic currently in Phase I development for acute respiratory distress syndrome.

Glaxo--which has a big focus on lung drugs--gets the exclusive rights to the drug in exchange for 12.7 million euros ($17.7 million) in cash and an equity investment. Milestone payments reach up to 239 million euros, or roughly $330 million. The disease has a mortality rate of 30 percent to 50 percent, and there is no approved therapy to treat it.

"When I returned to Austria after several years of basic research in North America, I had the vision of translating some of my research, including that for ACE2, into clinically useful and commercially viable products," says Josef Penninger, a scientist and founder of Apeiron. "I am impressed to see how quickly and successfully the basic idea was translated into a clinical project with such promising perspectives.

- check out the press release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.